Episode 1 of the Therapeutic Science and Strategy Podcast Series recorded by Cello Health, now part of Lumanity

In this first episode, Joel sits down with Michael Parisi, CEO of Guidemark, and Michael Rice, Vice President, Head of Advanced Therapeutics, to explore:

  • How uncovering non-small-cell lung cancer (NSCLC) and spinal muscular atrophy (SMA) genetics led to record-speed options for patients with rare subtypes
  • How the patient advocacy groups enabled translation
  • How the provider infrastructure is evolving to meet the need for genetic precision
  • What pharma brought upon entering and how the lessons shape their and field’s outlook
  • What’s next for rare disease drug development

Podcast Series: Therapeutic Science and Strategy

In this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead, sits down to talk about relevant and important content.